Back to top
more

Grifols (GRFS)

(Delayed Data from NSDQ)

$10.72 USD

10.72
554,397

-0.06 (-0.56%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $10.72 0.00 (0.00%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod

by Zacks Equity Research

Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.

    Zacks Equity Research

    AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

    by Zacks Equity Research

    London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.

      Zacks Equity Research

      Is Grifols a Great Stock for Value Investors?

      by Zacks Equity Research

      Let's focus on Grifols, S.A. (GRFS) stock and find out if it is a good choice for value-oriented investors right now or not.

        Zacks Equity Research

        Aurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session

        by Zacks Equity Research

        Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares rose above 8% on the day.

          Zacks Equity Research

          Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%

          by Zacks Equity Research

          Esperion Therapeutics, Inc. (ESPR) moved big last session, as its shares rose above 8% on the day.

            Tirthankar Chakraborty headshot

            New Strong Buy Stocks for March 9th

            by Tirthankar Chakraborty

            Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

              Zacks Equity Research

              Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5%

              by Zacks Equity Research

              Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise almost 7% in the last trading session.

                Zacks Equity Research

                Hologic (HOLX) to Divest Blood Screening Business to Grifols

                by Zacks Equity Research

                Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.

                  Kevin Matras headshot

                  The Power of New Analyst Coverage

                  by Kevin Matras

                  Kevin Matras shows why stocks with new analyst coverage are stocks you want to have. Highlighted stocks include GRFS, PRGN, GWRE, ABM and THG.